Long COVID: clues about causes
Felicity Liew, Claudia Efstathiou, Peter J.M. Openshaw
Eur Respir J, 61 (5) 2300409; 10.1183/13993003.00409-2023 |    |
Acute exacerbation of fibrotic interstitial lung disease beyond idiopathic pulmonary fibrosis: time to intervene
Ryoko Egashira, Ganesh Raghu
Eur Respir J, 61 (5) 2300459; 10.1183/13993003.00459-2023 | |
The art of clinical trial design in pulmonary fibrosis
Jürgen Behr
Eur Respir J, 61 (5) 2300346; 10.1183/13993003.00346-2023 | |
Improvement of air quality has a positive impact on lung growth, particularly during puberty
Anke Hüls
Eur Respir J, 61 (5) 2300345; 10.1183/13993003.00345-2023 | |
Air pollution and COPD: GOLD 2023 committee report
Don D. Sin, Dany Doiron, Alvar Agusti, Antonio Anzueto, Peter J. Barnes, Bartolome R. Celli, Gerard J. Criner, David Halpin, MeiLan K. Han, Fernando J. Martinez, Maria Montes de Oca, Alberto Papi, Ian Pavord, Nicolas Roche, Dave Singh, Robert Stockley, M. Victorina Lopez Varlera, Jadwiga Wedzicha, Claus Vogelmeier, Jean Bourbeau
Eur Respir J, 61 (5) 2202469; 10.1183/13993003.02469-2022 | |
Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID
Nicholas A. Scott, Laurence Pearmain, Sean B. Knight, Oliver Brand, David J. Morgan, Christopher Jagger, Sarah Harbach, Saba Khan, Halima A. Shuwa, Miriam Franklin, Verena Kästele, Thomas Williams, Ian Prise, Flora A. McClure, Pamela Hackney, Lara Smith, Madhvi Menon, Joanne E. Konkel, Criag Lawless, James Wilson, Alexander G. Mathioudakis, Stefan C. Stanel, Andrew Ustianowski, Gabriella Lindergard, Seema Brij, Nawar Diar Bakerly, Paul Dark, Christopher Brightling, Pilar Rivera-Ortega, Graham M. Lord, Alex Horsley, Karen Piper Hanley, Timothy Felton, Angela Simpson, John R. Grainger, Tracy Hussell, Elizabeth R. Mann
Eur Respir J, 61 (5) 2202226; 10.1183/13993003.02226-2022 | |
A predictive model for acute exacerbation of idiopathic interstitial pneumonias
Masato Karayama, Yoichiro Aoshima, Takahito Suzuki, Kazutaka Mori, Nobuko Yoshizawa, Shintaro Ichikawa, Shinpei Kato, Koshi Yokomura, Masato Kono, Dai Hashimoto, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Satoshi Goshima, Naoki Inui, Takafumi Suda
Eur Respir J, 61 (5) 2201634; 10.1183/13993003.01634-2022 | |
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study
Yet H. Khor, Max Schulte, Kerri A. Johannson, Veronica Marcoux, Jolene H. Fisher, Deborah Assayag, Helene Manganas, Nasreen Khalil, Martin Kolb, Christopher J. Ryerson
Eur Respir J, 61 (5) 2202163; 10.1183/13993003.02163-2022 | |
Minimal clinically important difference for impulse oscillometry in adults with asthma
Mustafa Abdo, Anne-Marie Kirsten, Erika von Mutius, Matthias Kopp, Gesine Hansen, Klaus F. Rabe, Henrik Watz, Frederik Trinkmann, Thomas Bahmer
Eur Respir J, 61 (5) 2201793; 10.1183/13993003.01793-2022 | |
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Isabelle Durieu, Reem Kanaan, Julie Macey, Dominique Grenet, Michele Porzio, Nathalie Coolen-Allou, Raphael Chiron, Christophe Marguet, Benoit Douvry, Nadine Dufeu, Isabelle Danner-Boucher, Pierre Foucaud, Lydie Lemonnier, Emmanuelle Girodon, Jennifer Da Silva, Clémence Martin
Eur Respir J, 61 (5) 2202437; 10.1183/13993003.02437-2022 | |
Associations of improved air quality with lung function growth from childhood to adulthood: the BAMSE study
Zhebin Yu, Simon Kebede Merid, Tom Bellander, Anna Bergström, Kristina Eneroth, Antonios Georgelis, Jenny Hallberg, Inger Kull, Petter Ljungman, Susanna Klevebro, Massimo Stafoggia, Gang Wang, Göran Pershagen, Olena Gruzieva, Erik Melén
Eur Respir J, 61 (5) 2201783; 10.1183/13993003.01783-2022 | |
Anti-anaerobic antibiotics: indication is key
G. Jan Zijlstra, Harm-Jan S. de Grooth
Eur Respir J, 61 (5) 2300318; 10.1183/13993003.00318-2023 | |
Reply to: Anti-anaerobic antibiotics: indication is key
Rishi Chanderraj, Jennifer M. Baker, Stephen G. Kay, Christopher A. Brown, Kevin J. Hinkle, Daniel J. Fergle, Roderick A. McDonald, Nicole R. Falkowski, Joseph D. Metcalf, Keith S. Kaye, Robert J. Woods, Hallie C. Prescott, Michael W. Sjoding, Robert P. Dickson
Eur Respir J, 61 (5) 2300492; 10.1183/13993003.00492-2023 | |
Empiric anti-anaerobic antibiotics are associated with adverse clinical outcomes in emergency department patients
Robert F.J. Kullberg, Michiel Schinkel, W. Joost Wiersinga
Eur Respir J, 61 (5) 2300413; 10.1183/13993003.00413-2023 | |
Moving towards patient-centred outcomes: the Severe Asthma Questionnaire
Drew Davies, Michael E. Hyland, Joseph W. Lanario, Rupert C. Jones, Matthew Masoli
Eur Respir J, 61 (5) 2202305; 10.1183/13993003.02305-2022 | |
Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex
Claudio U. Köser, Florian P. Maurer
Eur Respir J, 61 (5) 2202397; 10.1183/13993003.02397-2022 | |
The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series
Gunnar Kahlmeter, John Turnidge
Eur Respir J, 61 (5) 2202259; 10.1183/13993003.02259-2022 | |
Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis
Eur Respir J, 61 (5) 2300426; 10.1183/13993003.00426-2023 | |